A Research Study within the US Military Health System Deploys Clinical ink’s Self-Testing Mobile Platform to Understand Long COVID
Horsham, Pennsylvania, USA, Nov. 01, 2022 (GLOBE NEWSWIRE) — Clinical ink, a global life science technology company, has developed a self-testing app to measure cognitive impairment in patients diagnosed with COVID-19.
In a groundbreaking research study within the US Military Health System, Clinical ink’s self-testing mobile platform is being deployed among individuals both with and without COVID-19 to gain a better understanding of Long COVID. This innovative approach aims to provide valuable insights into the long-term effects of the virus on cognitive function and overall health.
The Impact on Individuals:
For individuals participating in this research study, the use of Clinical ink’s self-testing mobile platform offers a convenient and accessible way to monitor their cognitive function post-COVID-19 diagnosis. By regularly engaging with the app, participants can track any changes in their cognitive abilities and seek appropriate medical attention if needed. This proactive approach to long COVID management could lead to early intervention and better outcomes for affected individuals.
The Global Implications:
On a larger scale, the data collected from this research study has the potential to contribute valuable insights to the global medical community. By understanding the long-term effects of COVID-19 on cognitive function, healthcare providers and researchers can develop more targeted interventions and treatment strategies for individuals suffering from Long COVID. This knowledge could ultimately lead to improved long-term care and quality of life for COVID-19 survivors worldwide.
Conclusion:
The deployment of Clinical ink’s self-testing mobile platform within the US Military Health System for the research study on Long COVID represents a significant step forward in our understanding of the virus’s long-term effects. By leveraging innovative technology and data collection methods, this study has the potential to benefit both individuals impacted by COVID-19 and the global healthcare community as a whole.
